$NBSE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NeuBase Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NeuBase Therapeutics, Inc.. Get notifications about new insider transactions in NeuBase Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 2021 | NBSE | NeuBase Therapeuti ... | McDougall Gerald J | Director | Option Exercise | A | 4.91 | 92,219 | 452,795 | 92,219 | |
| Apr 27 2021 | NBSE | NeuBase Therapeuti ... | RICHMAN ERIC I | Director | Buy | P | 5.00 | 5,000 | 25,000 | 41,080 | 36.1 K to 41.1 K (+13.86 %) |
| Apr 27 2021 | NBSE | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Buy | P | 5.00 | 12,000 | 60,000 | 24,525 | 12.5 K to 24.5 K (+95.81 %) |
| Apr 27 2021 | NBSE | NeuBase Therapeuti ... | GOLDSTEIN DOV A MD | Director | Buy | P | 5.00 | 12,000 | 60,000 | 22,000 | 10 K to 22 K (+120.00 %) |
| Apr 27 2021 | NBSE | NeuBase Therapeuti ... | Mann William Roland | COO | Buy | P | 5.00 | 5,000 | 25,000 | 5,000 | 0 to 5 K |
| Dec 30 2020 | NBSE | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Option Exercise | A | 6.92 | 164,925 | 1,141,281 | 164,925 | |
| Dec 30 2020 | NBSE | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Gift | G | 0.00 | 1,273,820 | 0 | 1,273,819 | 2.5 M to 1.3 M (-50.00 %) |
| Dec 30 2020 | NBSE | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Gift | G | 0.00 | 1,273,819 | 0 | 2,547,639 | 3.8 M to 2.5 M (-33.33 %) |
| Dec 30 2020 | NBSE | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Gift | G | 0.00 | 1,273,819 | 0 | 2,547,639 | 3.8 M to 2.5 M (-33.33 %) |
| Dec 30 2020 | NBSE | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Gift | G | 0.00 | 2,547,639 | 0 | 2,547,639 | 5.1 M to 2.5 M (-50.00 %) |
| Dec 30 2020 | NBSE | NeuBase Therapeuti ... | Backenroth Samuel | CFO, Treasurer & Se ... | Option Exercise | A | 6.92 | 41,915 | 290,052 | 41,915 | |
| Sep 11 2020 | OHRP | NeuBase Therapeuti ... | GOLDSTEIN DOV A MD | Director | Option Exercise | A | 8.80 | 14,634 | 128,779 | 14,634 | |
| Sep 11 2020 | OHRP | NeuBase Therapeuti ... | Miralles Gines Diego | Director | Option Exercise | A | 8.80 | 14,634 | 128,779 | 14,634 | |
| Sep 11 2020 | OHRP | NeuBase Therapeuti ... | RICHMAN ERIC I | Director | Option Exercise | A | 8.80 | 14,634 | 128,779 | 14,634 | |
| Sep 11 2020 | OHRP | NeuBase Therapeuti ... | PRENDERGAST FRANKLYN G | Director | Option Exercise | A | 8.80 | 14,634 | 128,779 | 14,634 | |
| Jul 28 2020 | OHRP | NeuBase Therapeuti ... | Mann William Roland | COO | Option Exercise | A | 7.46 | 175,000 | 1,305,500 | 175,000 | |
| Jun 10 2020 | OHRP | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Buy | P | 7.73 | 1,275 | 9,861 | 12,525 | 11.3 K to 12.5 K (+11.33 %) |
| May 04 2020 | OHRP | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Buy | P | 6.00 | 10,000 | 60,000 | 10,000 | 0 to 10 K |
| May 04 2020 | OHRP | NeuBase Therapeuti ... | GOLDSTEIN DOV A MD | Director | Buy | P | 6.00 | 10,000 | 60,000 | 10,000 | 0 to 10 K |
| May 04 2020 | OHRP | NeuBase Therapeuti ... | Backenroth Samuel | CFO, Treasurer & Se ... | Buy | P | 6.00 | 1,000 | 6,000 | 11,630 | 10.6 K to 11.6 K (+9.41 %) |
| May 04 2020 | OHRP | NeuBase Therapeuti ... | RICHMAN ERIC I | Director | Buy | P | 6.00 | 8,333 | 49,998 | 36,080 | 27.7 K to 36.1 K (+30.03 %) |
| May 04 2020 | OHRP | NeuBase Therapeuti ... | RICHMAN ERIC I | Director | Buy | P | 6.00 | 2,500 | 15,000 | 27,747 | 25.2 K to 27.7 K (+9.90 %) |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | PRENDERGAST FRANKLYN G | Director | Option Exercise | A | 5.39 | 227,330 | 1,225,309 | 227,330 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | PRENDERGAST FRANKLYN G | Director | Option Exercise | A | 5.39 | 227,330 | 1,225,309 | 227,330 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Option Exercise | A | 0.00 | 3,311,930 | 3,312 | 3,311,930 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Option Exercise | A | 0.00 | 3,311,930 | 3,312 | 3,311,930 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Grant | A | 0.00 | 2,547,639 | 0 | 2,547,639 | 0 to 2.5 M |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Stephan Dietrich A | President and CEO | Grant | A | 0.00 | 2,547,639 | 0 | 2,547,639 | 0 to 2.5 M |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | RICHMAN ERIC I | Director | Option Exercise | A | 5.39 | 227,330 | 1,225,309 | 227,330 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | RICHMAN ERIC I | Director | Option Exercise | A | 5.39 | 227,330 | 1,225,309 | 227,330 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | RICHMAN ERIC I | Director | Grant | A | 0.00 | 25,247 | 0 | 25,247 | 0 to 25.2 K |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | RICHMAN ERIC I | Director | Grant | A | 0.00 | 25,247 | 0 | 25,247 | 0 to 25.2 K |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Miralles Gines Diego | Director | Option Exercise | A | 5.39 | 227,330 | 1,225,309 | 227,330 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Miralles Gines Diego | Director | Option Exercise | A | 5.39 | 227,330 | 1,225,309 | 227,330 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | GOLDSTEIN DOV A MD | Director | Option Exercise | A | 5.39 | 227,330 | 1,225,309 | 227,330 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | GOLDSTEIN DOV A MD | Director | Option Exercise | A | 5.39 | 227,330 | 1,225,309 | 227,330 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Backenroth Samuel | CFO, Treasurer & Se ... | Option Exercise | J | 10.14 | 3,000 | 30,420 | 0 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Backenroth Samuel | CFO, Treasurer & Se ... | Option Exercise | J | 10.14 | 3,000 | 30,420 | 0 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Backenroth Samuel | CFO, Treasurer & Se ... | Option Exercise | A | 5.39 | 772,923 | 4,166,055 | 772,923 | |
| Jul 16 2019 | OHRP | NeuBase Therapeuti ... | Backenroth Samuel | CFO, Treasurer & Se ... | Option Exercise | A | 5.39 | 772,923 | 4,166,055 | 772,923 | |
| Oct 18 2017 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Option Exercise | A | 0.67 | 350,000 | 234,500 | 350,000 | |
| Oct 18 2017 | OHRP | Ohr Pharmaceutical ... | Riedhammer Thomas M | Director | Option Exercise | A | 0.67 | 170,000 | 113,900 | 170,000 | |
| Oct 18 2017 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Option Exercise | A | 0.67 | 390,000 | 261,300 | 390,000 | |
| Oct 18 2017 | OHRP | Ohr Pharmaceutical ... | Almenoff June Sherie | Director | Option Exercise | A | 0.67 | 170,000 | 113,900 | 170,000 | |
| Oct 18 2017 | OHRP | Ohr Pharmaceutical ... | HIRSCHMAN ORIN | Director | Option Exercise | A | 0.67 | 245,000 | 164,150 | 245,000 | |
| May 16 2017 | OHRP | Ohr Pharmaceutical ... | Ferguson Michael | Director | Option Exercise | A | 0.65 | 750,000 | 487,500 | 750,000 | |
| Apr 13 2017 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Option Exercise | P | 1.00 | 100,001 | 100,001 | 100,001 | |
| Apr 13 2017 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 0.70 | 142,858 | 100,001 | 1,067,898 | 925 K to 1.1 M (+15.44 %) |
| Apr 13 2017 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Option Exercise | P | 1.00 | 50,001 | 50,001 | 50,001 | |
| Apr 13 2017 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 0.70 | 71,429 | 50,000 | 212,596 | 141.2 K to 212.6 K (+50.60 %) |
| Apr 13 2017 | OHRP | Ohr Pharmaceutical ... | HIRSCHMAN ORIN | Director | Option Exercise | P | 1.00 | 100,001 | 100,001 | 100,001 | |
| Apr 13 2017 | OHRP | Ohr Pharmaceutical ... | HIRSCHMAN ORIN | Director | Buy | P | 0.70 | 142,858 | 100,001 | 1,649,605 | 1.5 M to 1.6 M (+9.48 %) |
| Aug 02 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | J | 0.00 | 497,859 | 0 | 1,195,724 | 697.9 K to 1.2 M (+71.34 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 2.71 | 550 | 1,491 | 925,040 | 924.5 K to 925 K (+0.06 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 2.83 | 1 | 3 | 924,490 | 924.5 K to 924.5 K (0.00 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 2.84 | 5,431 | 15,424 | 924,489 | 919.1 K to 924.5 K (+0.59 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 2.87 | 1,019 | 2,925 | 919,058 | 918 K to 919.1 K (+0.11 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 2.88 | 85 | 245 | 918,039 | 918 K to 918 K (+0.01 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 2.89 | 1,700 | 4,913 | 917,954 | 916.3 K to 918 K (+0.19 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 2.71 | 200 | 542 | 141,167 | 141 K to 141.2 K (+0.14 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 2.84 | 1,800 | 5,112 | 140,967 | 139.2 K to 141 K (+1.29 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 2.87 | 450 | 1,292 | 139,167 | 138.7 K to 139.2 K (+0.32 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 2.88 | 8 | 23 | 138,717 | 138.7 K to 138.7 K (+0.01 %) |
| Jun 21 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 2.89 | 10 | 29 | 138,709 | 138.7 K to 138.7 K (+0.01 %) |
| May 26 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.10 | 2,000 | 6,200 | 916,254 | 914.3 K to 916.3 K (+0.22 %) |
| May 26 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.13 | 682 | 2,135 | 914,254 | 913.6 K to 914.3 K (+0.07 %) |
| May 26 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.14 | 100 | 314 | 913,572 | 913.5 K to 913.6 K (+0.01 %) |
| May 26 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.14 | 300 | 942 | 913,472 | 913.2 K to 913.5 K (+0.03 %) |
| May 26 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.11 | 100 | 311 | 913,172 | 913.1 K to 913.2 K (+0.01 %) |
| May 26 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.09 | 500 | 1,545 | 913,072 | 912.6 K to 913.1 K (+0.05 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.10 | 300 | 930 | 912,572 | 912.3 K to 912.6 K (+0.03 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.06 | 800 | 2,448 | 912,272 | 911.5 K to 912.3 K (+0.09 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.07 | 8 | 25 | 911,472 | 911.5 K to 911.5 K (0.00 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.09 | 100 | 309 | 911,464 | 911.4 K to 911.5 K (+0.01 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.07 | 2,595 | 7,967 | 911,364 | 908.8 K to 911.4 K (+0.29 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.09 | 700 | 2,163 | 908,769 | 908.1 K to 908.8 K (+0.08 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.08 | 1,600 | 4,928 | 908,069 | 906.5 K to 908.1 K (+0.18 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.12 | 200 | 624 | 906,469 | 906.3 K to 906.5 K (+0.02 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.15 | 200 | 630 | 906,269 | 906.1 K to 906.3 K (+0.02 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.16 | 100 | 316 | 906,069 | 906 K to 906.1 K (+0.01 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.17 | 500 | 1,585 | 905,969 | 905.5 K to 906 K (+0.06 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.14 | 200 | 628 | 905,469 | 905.3 K to 905.5 K (+0.02 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.13 | 200 | 626 | 905,269 | 905.1 K to 905.3 K (+0.02 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.11 | 267 | 830 | 905,069 | 904.8 K to 905.1 K (+0.03 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.12 | 1,337 | 4,171 | 904,802 | 903.5 K to 904.8 K (+0.15 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.13 | 89 | 278 | 903,465 | 903.4 K to 903.5 K (+0.01 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.13 | 803 | 2,513 | 903,376 | 902.6 K to 903.4 K (+0.09 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.14 | 357 | 1,121 | 902,573 | 902.2 K to 902.6 K (+0.04 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.15 | 1,516 | 4,775 | 902,216 | 900.7 K to 902.2 K (+0.17 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.16 | 3,121 | 9,862 | 900,700 | 897.6 K to 900.7 K (+0.35 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.17 | 6,851 | 21,718 | 897,579 | 890.7 K to 897.6 K (+0.77 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.18 | 1,588 | 5,050 | 890,728 | 889.1 K to 890.7 K (+0.18 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.19 | 1,248 | 3,981 | 889,140 | 887.9 K to 889.1 K (+0.14 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.20 | 446 | 1,427 | 887,892 | 887.4 K to 887.9 K (+0.05 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.21 | 1,516 | 4,866 | 887,446 | 885.9 K to 887.4 K (+0.17 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.22 | 89 | 287 | 885,930 | 885.8 K to 885.9 K (+0.01 %) |
| May 25 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.23 | 1,337 | 4,319 | 885,841 | 884.5 K to 885.8 K (+0.15 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.11 | 33 | 103 | 138,699 | 138.7 K to 138.7 K (+0.02 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.12 | 163 | 509 | 138,666 | 138.5 K to 138.7 K (+0.12 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.13 | 11 | 34 | 138,503 | 138.5 K to 138.5 K (+0.01 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.13 | 97 | 304 | 138,492 | 138.4 K to 138.5 K (+0.07 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.14 | 43 | 135 | 138,395 | 138.4 K to 138.4 K (+0.03 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.15 | 184 | 580 | 138,352 | 138.2 K to 138.4 K (+0.13 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.16 | 379 | 1,198 | 138,168 | 137.8 K to 138.2 K (+0.28 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.17 | 834 | 2,644 | 137,789 | 137 K to 137.8 K (+0.61 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.18 | 192 | 611 | 136,955 | 136.8 K to 137 K (+0.14 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.19 | 152 | 485 | 136,763 | 136.6 K to 136.8 K (+0.11 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.20 | 54 | 173 | 136,611 | 136.6 K to 136.6 K (+0.04 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.21 | 184 | 591 | 136,557 | 136.4 K to 136.6 K (+0.13 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.22 | 11 | 35 | 136,373 | 136.4 K to 136.4 K (+0.01 %) |
| May 24 2016 | OHRP | Ohr Pharmaceutical ... | Backenroth Samuel | Chief Financial Off ... | Buy | P | 3.23 | 163 | 526 | 136,362 | 136.2 K to 136.4 K (+0.12 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.41 | 100 | 341 | 878,254 | 878.2 K to 878.3 K (+0.01 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.44 | 100 | 344 | 878,154 | 878.1 K to 878.2 K (+0.01 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.46 | 200 | 692 | 878,054 | 877.9 K to 878.1 K (+0.02 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.49 | 100 | 349 | 877,854 | 877.8 K to 877.9 K (+0.01 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.50 | 100 | 350 | 877,754 | 877.7 K to 877.8 K (+0.01 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.55 | 100 | 355 | 877,654 | 877.6 K to 877.7 K (+0.01 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.57 | 100 | 357 | 877,554 | 877.5 K to 877.6 K (+0.01 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.58 | 100 | 358 | 877,454 | 877.4 K to 877.5 K (+0.01 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.59 | 100 | 359 | 877,354 | 877.3 K to 877.4 K (+0.01 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.60 | 400 | 1,440 | 877,254 | 876.9 K to 877.3 K (+0.05 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.61 | 300 | 1,083 | 876,854 | 876.6 K to 876.9 K (+0.03 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.63 | 2,200 | 7,986 | 876,554 | 874.4 K to 876.6 K (+0.25 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.64 | 200 | 728 | 874,354 | 874.2 K to 874.4 K (+0.02 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.65 | 300 | 1,095 | 874,154 | 873.9 K to 874.2 K (+0.03 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.66 | 327 | 1,197 | 873,854 | 873.5 K to 873.9 K (+0.04 %) |
| Mar 09 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.70 | 1,523 | 5,635 | 873,527 | 872 K to 873.5 K (+0.17 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.06 | 200 | 612 | 872,004 | 871.8 K to 872 K (+0.02 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.07 | 300 | 921 | 871,804 | 871.5 K to 871.8 K (+0.03 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.08 | 500 | 1,540 | 871,504 | 871 K to 871.5 K (+0.06 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.09 | 200 | 618 | 871,004 | 870.8 K to 871 K (+0.02 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.10 | 100 | 310 | 870,804 | 870.7 K to 870.8 K (+0.01 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.11 | 3,550 | 11,041 | 870,704 | 867.2 K to 870.7 K (+0.41 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.12 | 700 | 2,184 | 867,154 | 866.5 K to 867.2 K (+0.08 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.13 | 200 | 626 | 866,454 | 866.3 K to 866.5 K (+0.02 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.14 | 100 | 314 | 866,254 | 866.2 K to 866.3 K (+0.01 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.15 | 300 | 945 | 866,154 | 865.9 K to 866.2 K (+0.03 %) |
| Feb 23 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.21 | 100 | 321 | 865,854 | 865.8 K to 865.9 K (+0.01 %) |
| Apr 12 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.35 | 6,250 | 20,938 | 884,504 | 878.3 K to 884.5 K (+0.71 %) |
| Jan 26 2016 | OHRP | Ohr Pharmaceutical ... | GREENSTEIN IRA A | Director | Option Exercise | A | 3.62 | 80,000 | 289,600 | 80,000 | |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.52 | 200 | 704 | 865,754 | 865.6 K to 865.8 K (+0.02 %) |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.52 | 100 | 352 | 865,554 | 865.5 K to 865.6 K (+0.01 %) |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.53 | 1,000 | 3,530 | 865,454 | 864.5 K to 865.5 K (+0.12 %) |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.54 | 1,200 | 4,248 | 864,454 | 863.3 K to 864.5 K (+0.14 %) |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.55 | 850 | 3,018 | 863,254 | 862.4 K to 863.3 K (+0.10 %) |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.56 | 100 | 356 | 862,404 | 862.3 K to 862.4 K (+0.01 %) |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.57 | 100 | 357 | 862,304 | 862.2 K to 862.3 K (+0.01 %) |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.59 | 400 | 1,436 | 862,204 | 861.8 K to 862.2 K (+0.05 %) |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.60 | 200 | 720 | 861,804 | 861.6 K to 861.8 K (+0.02 %) |
| Jan 20 2016 | OHRP | Ohr Pharmaceutical ... | Slakter Jason Scott | Chief Executive Off ... | Buy | P | 3.65 | 200 | 730 | 861,604 | 861.4 K to 861.6 K (+0.02 %) |